August 13, 2008

Proposed Acquisition of Talecris Biotherapeutics by CSL Limited

A proposed combination of two leaders in the plasma therapeutics industry, Talecris Biotherapeutics and CSL Behring, has been announced. CSL Limited, the parent company of CSL Behring, announced it proposes to acquire Talecris Biotherapeutics and merge it into CSL Behring. The Immune Deficiency Foundation is following this development on behalf of our patient community. Both companies produce a large percentage of the immunoglobulin products that individuals in our community depend on for their lives. Representing a small and vulnerable patient community, IDF welcomes dialogues with representatives of each of the companies regarding the long term ramifications of a potential merger of this magnitude, including how this may impact the tight supply of immunoglobulin products, continued access to these products, future research and development, and the viability of critical patient and research programs supported by these companies.

About The Immune Deficiency Foundation

The Immune Deficiency Foundation, founded in 1980, is the national non-profit patient organization dedicated to improving the diagnosis, treatment and quality of life of persons with primary immunodeficiency diseases through advocacy, education and research.

In the United States, there are approximately 250,000 people diagnosed with primary immunodeficiency disease and thousands more go undetected. These individuals often find it difficult to receive specialized health care, proper diagnosis and treatment. Individuals affected by primary immunodeficiency diseases also experience difficulties financing their health care, finding educational materials on the disease and locating others with whom to share their experiences. The mission of IDF is to help individuals overcome these difficulties and live healthy and productive lives. The constant presence of IDF assures patients, their families and their medical caretakers that there is a place to turn for help.